Aardvark Therapeutics (AARD) awards director 44,964 stock options

Rhea-AI Filing Summary

Aardvark Therapeutics, Inc. (AARD) reported that director Victor Edward Tong Jr received a grant of stock options for 44,964 shares of common stock at an exercise price of $6.54 per share. These options vest in full on the earlier of August 14, 2027 or immediately prior to the next Annual Meeting of Stockholders, subject to continuous service, and expire on August 14, 2036. Following this award, Tong holds 44,964 option shares from this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tong Victor Edward Jr

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	44,964	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 44,964 shares (Direct)

Footnotes (1)

1. F1. The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.

Key Figures

Stock options granted: 44,964 shares Exercise price: $6.54 per share Expiration date: August 14, 2036 +2 more

5 metrics

Stock options granted 44,964 shares Grant of Stock Option (right to buy) to director Victor Edward Tong Jr on 2026-08-14

Exercise price $6.54 per share Conversion or exercise price of the Stock Option (right to buy)

Expiration date August 14, 2036 Expiration date of the granted stock options

Vesting date reference August 14, 2027 Options vest on the earlier of August 14, 2027 or immediately prior to the next Annual Meeting of Stockholders

Options held after transaction 44,964 shares Total option shares from this grant following the reported acquisition

Key Terms

Stock Option (right to buy), vest in full, Annual Meeting of Stockholders

3 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

vest in full financial

"The option shall vest in full on the earlier of"

Annual Meeting of Stockholders regulatory

"immediately prior to the Registrant's next Annual Meeting of Stockholders"

FAQ

What insider transaction did AARD report for Victor Edward Tong Jr?

Aardvark Therapeutics (AARD) reported that director Victor Edward Tong Jr received a grant of stock options for 44,964 shares of common stock as a compensation-related award.

What is the exercise price of the new stock options granted by AARD?

The stock options granted to Victor Edward Tong Jr by Aardvark Therapeutics (AARD) have an exercise price of $6.54 per share for the underlying common stock.

When do Victor Edward Tong Jr’s AARD options vest?

The options vest in full on the earlier of August 14, 2027 or immediately prior to Aardvark Therapeutics’ next Annual Meeting of Stockholders, subject to his continuous service through the applicable vesting date.

When do the new AARD stock options held by Victor Edward Tong Jr expire?

The stock options granted to Victor Edward Tong Jr by Aardvark Therapeutics (AARD) have an expiration date of August 14, 2036, if not earlier exercised or forfeited under the plan terms.

How many AARD option shares does Victor Edward Tong Jr hold after this grant?

Following this transaction, Victor Edward Tong Jr holds 44,964 option shares from this reported grant of stock options for Aardvark Therapeutics (AARD) common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 07:45 PM Accepted by SEC EDGAR 08/21/2026 - 07:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tong Victor Edward Jr

(Last) (First) (Middle)

C/O AARDVARK THERAPEUTICS, INC.

4370 LA JOLLA VILLAGE DRIVE, SUITE 1050

(Street)

SAN DIEGO CALIFORNIA 92122

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aardvark Therapeutics, Inc. [ AARD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.54	08/14/2026		A		44,964		(1)	08/14/2036	Common Stock	44,964	$0.00	44,964	D

Explanation of Responses:

1. The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.

	/s/ Nelson Sun, as Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)